Spotlight
The genetics of autism spectrum disorder have been studied intensively for two decades. Researchers have catalogued hundreds of mutations, each conferring elevated risk, many with clear mechanistic explanations for how they interfere with brain development. What has proven harder to explain is the clinical uniformity. Children with very different mutations often share overlapping profiles. The gene is different; the outcome rhymes.
A Nature paper from a collaboration spanning ISTA, Medical University of Vienna, University of Vienna, and CeMM, led by Lena Schwarz, suggests the answer lies not in which gene is disrupted but in when the disruption occurs. The team profiled eleven mouse models carrying different autism-linked mutations across the stages of cortical development. Despite their genetic diversity, the mutations converged on the same process: they each imposed a transient delay in a narrow developmental window, a shared stumble the brain largely resolves in the weeks after birth.
The implication is significant. If the convergence point is temporal rather than molecular, interventions aimed at individual pathways may be working on the wrong variable. The relevant question shifts from what the mutation does to when the developmental process it disrupts takes place. That reframing opens new territory for treatment design — and suggests that the brain's own postnatal recovery capacity may be a more tractable target than the upstream genetics.
Vienna's neuroscience cluster, spanning ISTA's basic research mission, CeMM's molecular medicine programme, and the clinical reach of MedUni Wien, is precisely positioned to translate a finding like this across levels of analysis — from molecular mechanism to developmental trajectory to potential clinical application.
Radar Scans
Funding Moves
The European Research Council announced its Advanced Grant class of 2025. Each award carries approximately EUR 2.5 million over five years for established researchers at the frontier of their field. Nine of Austria's twelve winners are based in Vienna.
WWTF Insight
Two WWTF-funded projects published this period. Thomas Wekerle (LS18-031, Life Sciences 2018, now completed) reports a proof-of-concept kidney-transplant trial in Science Translational Medicine: six patients achieved immune tolerance without irradiation, a result that, if it scales, would remove one of the most damaging steps in the transplant preparation protocol.
Nuno Maulide (LS21-010, Life Sciences 2021, active) publishes in Nature Chemistry a method for editing drug molecules at late synthesis stages — changing a structural feature of a nearly-finished compound rather than rebuilding it from scratch. The practical value for pharmaceutical development is immediate: late-stage diversification compresses the iteration cycle between lead compound and clinical candidate.
The two projects span medicine's two longest timelines: organ transplant immunology, where the field has sought reliable tolerance induction for fifty years, and drug synthesis, where shortening the path from molecule to medicine is a persistent bottleneck. A single funding call, eight years apart, now producing results at both ends.
Stray Signal
Vienna's social housing model as an export product
Vienna's housing stock is approximately 43 percent subsidised rental — a share unmatched in any comparable city. The policy dates to the 1920s, when Red Vienna began building at a scale that treated affordable shelter as infrastructure rather than welfare. A century later, the city still holds the accumulated stock. Judith M. Lehner at TU Wien and Andreas Scheba wrote about this for The Conversation, framing it against South Africa's housing shortage of 2.6 million homes — a context where the Viennese model is studied not as history but as a live option.
The piece raises the obvious question. If the policy worked at the scale of a European capital, what does replication actually require? Land, political continuity, and the willingness to hold public assets across multiple election cycles. None of those are technical constraints. The paper does not claim Vienna is transplantable. It does claim the model is worth understanding precisely.
Endnote
Markus Aspelmeyer (University of Vienna and Austrian Academy of Sciences) receives the 2026 FWF Wittgenstein Award — Austria's highest science prize — for work investigating whether gravity obeys quantum physics rules. His group at the University of Vienna has spent more than a decade building the experiments needed to ask that question. The award carries EUR 1.5 million in unrestricted research funding. Meanwhile, this fortnight's nine ERC Advanced Grants bring approximately EUR 22.5 million in new European funding to Vienna-based researchers.